242 related articles for article (PubMed ID: 35738604)
1. Circulating microRNAs and Clinicopathological Findings of Papillary Thyroid Cancer: A Systematic Review.
Geropoulos G; Psarras K; Papaioannou M; Giannis D; Meitanidou M; Kapriniotis K; Symeonidis N; Pavlidis ET; Pavlidis TE; Sapalidis K; Ahmed NM; Abdel-Aziz TE; Eddama MMR
In Vivo; 2022; 36(4):1551-1569. PubMed ID: 35738604
[TBL] [Abstract][Full Text] [Related]
2. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
3. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
4. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
5. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
6. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
Han PA; Kim HS; Cho S; Fazeli R; Najafian A; Khawaja H; McAlexander M; Dy B; Sorensen M; Aronova A; Sebo TJ; Giordano TJ; Fahey TJ; Thompson GB; Gauger PG; Somervell H; Bishop JA; Eshleman JR; Schneider EB; Witwer KW; Umbricht CB; Zeiger MA
Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846
[TBL] [Abstract][Full Text] [Related]
7. Association of MicroRNA Expression and BRAF
Pamedytyte D; Simanaviciene V; Dauksiene D; Leipute E; Zvirbliene A; Sarauskas V; Dauksa A; Verkauskiene R; Zilaitiene B
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32316638
[TBL] [Abstract][Full Text] [Related]
8. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
Tufano RP; Teixeira GV; Bishop J; Carson KA; Xing M
Medicine (Baltimore); 2012 Sep; 91(5):274-286. PubMed ID: 22932786
[TBL] [Abstract][Full Text] [Related]
9. Cyto-Histological Profile of MicroRNAs as Diagnostic Biomarkers in Differentiated Thyroid Carcinomas.
Matos ML; Pinto M; Alves M; Canberk S; Gonçalves A; Bugalho MJ; Papoila AL; Soares P
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540448
[TBL] [Abstract][Full Text] [Related]
10. Risk and Prognostic Factors for BRAF
Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.
Li C; Lee KC; Schneider EB; Zeiger MA
J Clin Endocrinol Metab; 2012 Dec; 97(12):4559-70. PubMed ID: 23055546
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA Deregulation in Papillary Thyroid Cancer and its Relationship With BRAF V600E Mutation.
Celakovsky P; Kovarikova H; Chrobok V; Mejzlik J; Laco J; Vosmikova H; Chmelarova M; Ryska A
In Vivo; 2021; 35(1):319-323. PubMed ID: 33402480
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma.
Yip L; Kelly L; Shuai Y; Armstrong MJ; Nikiforov YE; Carty SE; Nikiforova MN
Ann Surg Oncol; 2011 Jul; 18(7):2035-41. PubMed ID: 21537871
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer.
Lee JC; Zhao JT; Clifton-Bligh RJ; Gill A; Gundara JS; Ip JC; Glover A; Sywak MS; Delbridge LW; Robinson BG; Sidhu SB
Cancer; 2013 Dec; 119(24):4358-65. PubMed ID: 24301304
[TBL] [Abstract][Full Text] [Related]
15. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
Xing M
Endocr Rev; 2007 Dec; 28(7):742-62. PubMed ID: 17940185
[TBL] [Abstract][Full Text] [Related]
16. Prognostic utility of BRAF mutation in papillary thyroid cancer.
Xing M
Mol Cell Endocrinol; 2010 May; 321(1):86-93. PubMed ID: 19883729
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
18. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma.
Zhang Q; Liu SZ; Zhang Q; Guan YX; Chen QJ; Zhu QY
Cell Physiol Biochem; 2016; 38(2):763-76. PubMed ID: 26871894
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA Expression and Association with Clinicopathologic Features in Papillary Thyroid Cancer: A Systematic Review.
Aragon Han P; Weng CH; Khawaja HT; Nagarajan N; Schneider EB; Umbricht CB; Witwer KW; Zeiger MA
Thyroid; 2015 Dec; 25(12):1322-9. PubMed ID: 26414548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
